secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001171843-23-005101
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q2 net loss $30.5M ($0.65/sh); Phase 2 CSU enrollment complete, topline by YE 2023
--------------------------------------------------------------------------------

- Net loss of $30.5M ($0.65/sh) for Q2 2023 vs $36.0M ($0.77/sh) in Q2 2022; cash $252.7M.
- Phase 2 CSU enrollment completed with 208 patients, 25% above target; topline data expected by YE 2023.
- Phase 1b PN data planned for Q4 2023; Phase 2 EoE initiated, first patient dosed in July.
- R&D expenses increased to $26.3M from $20.7M YoY, driven by barzolvolimab costs.
- Cash runway sufficient through 2025 to fund planned Phase 2 studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/0001171843-23-005101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/f8k_080823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer